Evoke Pharma Inc (EVOK) Earnings Report, Financial Results, Financial analysis

Evoke Pharma Inc increased first quarter of 2023 net loss per share of $-0.67 compare to net loss per share of $-0.07 recorded in the same quarter a year ago a decrease compare to $-0.57 realized in previous quarter.

*first quarter of 2023*
Earnings Per Share	Revenues
$ -0.67	$ 1 Mill
$-0.60	Unch. +93.7 %

Evoke Pharma Inc 's Revenue rose by 93.7 % in first quarter of 2023 (Mar 31 2023) year on year, to $1 million and advanced by 1.76 % sequentially.

Evoke Pharma Inc is Expected to report next financial results on August 09, 2023.

More on EVOK's Income Statement

EVOK's NET INCOME

Evoke Pharma Inc 's in thefirst quarter of 2023 recorded net loss of $-2.243 million, an increase from net loss of $-2.174 million in I. Quarter a year ago.

Sequentially net loss advanced

More on EVOK's Growth

Evoke Pharma Inc Inventories
Inventories grew by 30.88 % to $0 million from I. Quarter a year ago, sequentially inventories rose by 26.09 %. In Mar 31 2023 company's net cash and cash equivalents decreased by $-2 million

Earnings quality

Evoke Pharma Inc does not pay out common stock dividend.

In trailing twelve-month period Evoke Pharma Inc payed $ -1.98 cash per share, on a free-cash flow basis .

Book value fell by -50.85 % sequentially to $0.64 per share, -25.79% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.64 per share from $ 1.29.

Company issued 0.19 million shares or 5.90 % in Mar 31 2023.

• More on EVOK's Dividends

Market Capitalization (Millions)	6
Shares Outstanding (Millions)	3
Total Debt (Millions $)	5
Revenue (TTM) (Millions $)	3
Net Income (TTM) (Millions $)	-8
Cash Flow (TTM) (Millions $)	1
Capital Exp. (TTM) (Millions $)	0
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	-

Earnings quality

Evoke Pharma Inc does not pay out common stock dividend.

In trailing twelve-month period Evoke Pharma Inc had negative $ -1.98 cash flow per share, on a free-cash flow basis .

Book value fell by -50.85 % sequentially to $0.64 per share, -25.79% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.64 per share from $ 1.29.

Company issued 0.19 million shares or 5.90 % in Mar 31 2023.

• More on EVOK's Balance Sheets

Market Capitalization (Millions)	6
Shares Outstanding (Millions)	3
Total Debt (Millions $)	5
Revenue (TTM) (Millions $)	3
Net Income (TTM) (Millions $)	-8
Cash Flow (TTM) (Millions $)	1
Capital Exp. (TTM) (Millions $)	0
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	-

Evoke Pharma Inc

EVOK's Financial Statements and Analysis